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Abstract
Background: Broad-band UVA, long-wave UVA1 and PUVA treatment have been described as an
alternative/adjunct therapeutic option in a number of inflammatory and malignant skin diseases.
Nevertheless, controlled studies investigating the efficacy of UVA irradiation in connective tissue
diseases and related disorders are rare.
Methods: Searching the PubMed database the current article systematically reviews established
and innovative therapeutic approaches of broad-band UVA irradiation, UVA1 phototherapy and
PUVA photochemotherapy in a variety of different connective tissue disorders.
Results: Potential pathways include immunomodulation of inflammation, induction of collagenases
and initiation of apoptosis. Even though holding the risk of carcinogenesis, photoaging or UV-
induced exacerbation, UVA phototherapy seems to exhibit a tolerable risk/benefit ratio at least in
systemic sclerosis, localized scleroderma, extragenital lichen sclerosus et atrophicus,
sclerodermoid graft-versus-host disease, lupus erythematosus and a number of sclerotic rarities.
Conclusions: Based on the data retrieved from the literature, therapeutic UVA exposure seems
to be effective in connective tissue diseases and related disorders. However, more controlled
investigations are needed in order to establish a clear-cut catalogue of indications.
Background
Unlike UVB radiation that can penetrate at the most into
the papillary dermis, longer wavelengths in the UVA
region have the capacity to reach the subcutis as well.
Accordingly, as well as due to its lesser antiproliferative
activity, UVB irradiation has not been established in the
treatment of sclerotic disorders except for occasional cases
of graft-versus-host disease (GvHD) [1,2]. Hence, this
review examines different modalities of UVA photother-
apy in the treatment of connective tissue diseases and
related disorders.
The term irradiance (e.g., in mW/cm2), which is the most
commonly used term in photobiology, relates to the
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subject (e.g., patient) struck by the irradiation. In photo-
biology, the time integral of the irradiance is commonly
expressed as fluence (e.g., in J/cm2), or even more loosely
as dose [3,4]. Even though mostly combined with 8-meth-
oxypsoralene or other photochemotherapeutic agents,
broad-band UVA irradiation (315–400 nm), containing
both UVA1 (340–400 nm) and UVA2 (315–340 nm), was
used as monotherapy e.g. in the treatment of atopic der-
matitis [5]. However, this phototherapeutic option was
being replaced more frequently by the usage of irradiation
devices which allow a more effective treatment by the
administration of selected spectra. By eliminating shorter
wavelengths in the UVA2 region adverse effects such as
erythema are minimized and therapeutically effective
higher UV doses can be administered. Thus, today broad-
band UVA may play a subordinated role in modern pho-
totherapy anymore, except for the combined application
with psoralenes, even though it is still used for a large
number of patients due to its wide availability and
although it has not yet been directly compared with UVA1
for many sclerosing disorders. Conventional UVA1 treat-
ment emitts wavelengths mainly between 340 and 400
nm, but may also produce scattered radiation >530 nm
including infrared irradiation (780–3000 nm). Three dif-
ferent pattern of UVA1 dosage have been described: high-
dose UVA1 phototherapy applying UVA1 doses ranging
from 90–130 J/cm2 single (975–1840 J/cm2 cumulative)
irradiation, medium-dose UVA1 phototherapy admitting
doses between 20–90 J/cm2 single (300–975 J/cm2 cumu-
lative) UVA1 and last but not least low-dose UVA1 photo-
therapy administering single UVA1 doses of ≤ 20 J/cm2 or
a cumulative doage ≤ 300 J/cm2, respectively [6-9]. Con-
ventional UVA1 phototherapy may be accompanied by
extensive heat load predominantly generated by infrared
irradiation (780–3000 nm) and/or insufficient cooling
systems of the phototherapy devices. For this reason,
within the last years, lavish new UVA1 equipment was
developed containing a special filtering and cooling sys-
tem, in which a considerable amount of wavelengths
>530 nm are eliminated and consequently the heat load
due to heat-producing infrared radiation is strongly
diminished [10]. Since more than two decades, the com-
bination of oral 5- or 8-methoxypsoralen followed by
broad-band UVA exposure is an effective treatment option
in a widespread number of indications such as psoriasis
and cutaneous T cell lymphoma [11-13]. Psoralens specif-
ically belong to the best characterized agents of photosen-
sitizing chemicals. Following its administration low-dose
UVA irradiation is applied including an individual pro-
gression depending on the formation of the so-called
PUVA erythema. In general, the overall mean cumulative
dose has been found to comprise ≤ 400 J/cm2 UVA [14].
In contrast to systemic PUVA therapy topical PUVA, for
example applied as PUVA bath, PUVA shower or PUVA
cream, is mainly characterized by absent/reduced sys-
temic side effects and the restriction to a selective limited
lesional area [15]. As a consequence, systemic PUVA has
mostly been replaced by topical PUVA treatment repre-
senting an efficient well-tolerable alternative to oral meth-
oxypsoralen administration. Generally, overall mean
cumulative dosage has been found to comprise ≤ 200 J/
cm2 UVA [14].
Different types of UVA phototherapy were introduced as
an innovative and promising therapeutic option in the
treatment of inflammatory diseases such as atopic derma-
titis and more recently in therapy of lymphoproliferative
disorders such as cutaneous T cell lymphoma and related
skin affections. No more than seven years ago, subsequent
to promising clinical results of extracorporeal photoche-
motherapy and psoralene plus UVA (PUVA) in systemic
sclerosis (SSc) and morphea [16-19], first investigations
have verified the therapeutic value of UVA1 irradiation for
the treatment of localized scleroderma (LS) [20-22].
However, encouraged by the clinical success and the
diversity of immunomodulatory effects achieved by the
use of UVA phototherapeutic regimens in a great number
of different indications, additional studies focused on
investigating the efficacy of UVA phototherapy in the
treatment of a widespread range of sclerotic skin diseases
[23]. Furthermore, series of UVA exposure may be used in
the treatment of lupus erythematosus (LE), even if known
as a photosensitive condition.
Today, different forms of UVA phototherapy are widely
used and have subsequently developed into a treatment
modality of importance within the field of dermatology
and rheumatology at least as an adjunctive treatment and,
beside the 'initial indications', may also or even especially
be indicated as a successful alternative in the treatment of
skin manifestations of connective tissue diseases and
related disorders.
Methods
For this systematic review we concentrated on the thera-
peutic use of UVA application in humans. The computer-
ized bibliographic database PubMed (includes all
citations from Medline and additional life science jour-
nals) without time limits (January 1966 to April 2004)
was screened for original papers, case reports, letters,
reviews and book articles on UVA/UVA1/PUVA. As main
key words we used "UVA", "UV-A", "UVA phototherapy",
"UVA1", "UV-A1" "UVA1 phototherapy", "PUVA",
"PUVA phototherapy", "PUVA photochemotherapy",
"ultraviolet A", "ultraviolet A1", "sclerosis", "sclero-
derma", "sclerosus", "sclerotic", "sclerodermoid", "mor-
phea", and "lupus erythematosus". Other sources
included monographs, textbooks, and the reference lists
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selected by two authors (F.B., T.G.) Inclusion or exclusion
of articles were based on consensus. Relevant data includ-
ing study design, number of patients, duration of treat-
ment, clinical outcome, cumulative UVA doses, and
adverse effects were retrieved from the articles, summa-
rized and briefly discussed as follows.
Results
Systemic sclerosis
SSc, affecting the connective tissue of various organs
including the skin, is histologically recognized by an alter-
ation of the microvasculature with a rarefaction of the ves-
sels within the papillary layer, perivascular skin
infiltrating T lymphocytes (mainly due to an alteration of
the Th2 immune response), rapid proliferation of dermal
fibroblasts exhibiting an elevated status of protein synthe-
sis and by a resulting massive deposition of collagen in
both the skin and internal organs [24-27].
UVA1
So far UVA1 phototherapy has only been reported to be
effective in the clearance of acral sclerotic skin lesions of
SSc patients by administering local UVA1 irradiation of
the hands or forearms, respectively. First, Kobyletzki et al.
reported on preliminary results about the efficacy of low-
dose UVA1 phototherapy within the treatment of acro-
sclerosis in eight patients suffering from progressive SSc
[28]. Exposure of 30 J/cm2 UVA1 was administered four
times per week for eight weeks and subsequent three times
per week for six weeks resulting in a total of 50 sessions
and a cumulative dose of 1500 J/cm2. In 2000, Morita et
al. could confirm the UVA1-induced softening of sclerosis
following partial body 60 J/cm2 medium-dose UVA1 pho-
totherapy ranging from 510 to 1740 J/cm2 cumulative
dose in three patients with diffuse and one with limited
SSc, later further underlined by decreased dermal decorin
levels as published in 2003 [29,30]. A recent open non-
randomized study including 18 patients with SSc derived
acrosclerosis revealed softening of former stiffness, an
increase of total skin distension, the reduction of skin
thickness and an elevation of dermal collagenase activity
in 16 patients following the corresponding irradiation
protocol as described by Kobyletzki et al. [31]. However,
whole-body UVA1 phototherapy has not yet been
described, although a possible systemic impact due to the
deep penetration depth seems to be imminent.
PUVA
Based on first studies reporting the efficacy of topical
PUVA in one patient with SSc [7], Kanekura et al.
described the positive outcome of former sclerotic lesions
in three patients exhibiting cutaneous manifestation of
progressive SSc [32]. PUVA was administered for three to
eight weeks with daily doses of 0.25 J/cm2 to 0.4 J/cm2
(cumulative dosage: 3.5 J/cm2 to 9.6 J/cm2) resulting in
remarkable clinical improvement of skin sclerosis index as
well as stiffed fingers, hands and knees. Another small
uncontrolled study investigated oral PUVA therapy for
SSc. The study included four women suffering from SSc
receiving a PUVA protocol consisting of 0.5 to 4 J/cm2 sin-
gle dose UVA given three times a week for ten weeks and
a mean cumulative dose of 70.5 J/cm2 UVA. Even though
posttherapeutic skin severity scores did not alter signifi-
cantly, at least microscopic analysis of the histological
skin scores of all patients revealed visible improvements
[33]. The last case report appeared in 2003 discussing the
UVA1 phototherapy in systemic sclerosis Figure 1
UVA1 phototherapy in systemic sclerosis. Clinical 
appearence of acrosclerotic piece-meal necrosis of the first 
digit in SSc before (Fig. 1) and almost complete clearance fol-
lowing low-dose UVA1 phototherapy (Fig. 2).
UVA1 phototherapy in systemic sclerosis Figure 2
UVA1 phototherapy in systemic sclerosis. Clinical 
appearence of acrosclerotic piece-meal necrosis of the first 
digit in SSc before (Fig. 1) and almost complete clearance fol-
lowing low-dose UVA1 phototherapy (Fig. 2).BMC Dermatology 2004, 4:11 http://www.biomedcentral.com/1471-5945/4/11
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use of PUVA bath in a young girl, proposing that PUVA
bath could also be used in childhood [34].
Localized scleroderma
LS is characterized by circumscribed fibrotic plaques gen-
erally affecting the whole dermis. Thus LS, particularly
when occurring in childhood, may contribute to progres-
sive and long-lasting induration of the skin and subcuta-
neous tissue, growth retardation, muscle atrophy and, in
severe cases, even to flexion deformities and poorly heal-
ing ulcerations [35].
UVA
As to our knowledge, there has been conducted only two
large study investigating low-dose broad-band UVA expo-
sure in morphea [36,37]. Twelve patients were irradiated
by doses of 20 J/cm2 broad-band UVA three times a week
for a total of 20 sessions (400 J/cm2 cumulative dose). Fol-
lowing treatment, all patients experienced marked soften-
ing of former skin lesions accompanied by significant
reduction of the mean concentration of collagen. Addi-
tionally, nine patients received 10 J/cm2 UVA single and
200 J/cm2 UVA cumulative dose. Even though different
study parameters varied between both groups, no statisti-
cally significant differences could be detected in the clini-
cal response to those doses.
UVA1
High-dose UVA1 phototherapy of LS has been introduced
by Stege et al. in 1997 [38]. Ten patients receiving 130 J/
cm2 high-dose UVA1 therapy (30 sessions, 3900 J/cm2
UVA1 cumulative dose) were compared with seven
patients treated by low-dose UVA1 phototherapy (30 ses-
sions, 600 J/cm2 cumulative dosage) and internal con-
trols. The authors state that high-dose UVA1 significantly
reduced skin thickness and stiffness and increased elastic-
ity of plaques. High-dose UVA1 was superior to low-dose
UVA1. By contrast, a number of different studies and case
series could also confirm the effectiveness of low-dose
UVA1 phototherapy. In 1995, Kerscher et al. were able to
discuss the first successful phototherapeutic approach of
low-dose UVA1 phototherapy of LS [39]. Subsequently,
the authors conducted a larger study including 20 patients
suffering from LS. Patients were irradiated with low-dose
UVA1 for twelve weeks (total of 30 treatment sessions, 20
J/cm2 single dose, 600 J/cm2 cumulative dose) resulting in
significant clinical improvement in about 80% of the
patients [20]. Two patients exhibiting subcutaneous LS
did not improve. Finally, Gruss et al. analyzed and com-
pared the effect of their low-dose UVA1 irradiation proto-
col on late-stage lesions, inflammatory lesions and late-
stage lesions with overlying lichen sclerosus et atrophicus
(LSA) [40]. All three patients responded well to therapy.
In addition to low- and high-dose UVA1, medium-dose
UVA1 phototherapy stands for a further phototherapeutic
option. In 2001, seven patients with morphea were
treated by 30 J/cm2 medium-dose UVA1 phototherapy
three times weekly during a ten week period [41]. All
patients reported improvement as judged by softening of
the skin lesions. Recently, controlled medium-dose UVA1
treatment was performed in a total of eight patients using
48 J/cm2 UVA1 [42]. Irradiation was administered four
times per week for twelve weeks resulting in an improve-
ment of skin sclerosis by a cumulative dose of 2304 J/cm2
UVA1. Furthermore, combined therapy with calcipotriol
ointment and low-dose UVA1 phototherapy seems to be
highly effective at least in childhood morphea. Following
a first case report, Kreuter et al. conducted a large open
prospective study including 19 children suffering from LS
[43,44]. UVA1 exposure was given four times a week for
ten weeks (20 J/cm2 single dose UVA1, cumulative dose:
800 J/cm2) as an adjunct to twice daily topical calcipotriol
application. Combined therapy resulted in a relative
reduction of clinical scores of about 67%. Its successful
use has also been reported regarding the variant of LS en
coup de sabre (30 J/cm2 UVA1, 30 sessions) [45].
PUVA
First application of PUVA bath photochemotherapy in
two cases of LS was published in 1994 by Kerscher et al.
UVA irradiation was administered once daily four times a
week for five consecutive weeks followed by twice per
week for additional five weeks (30 treatments, maximum
single dose of 20 J/cm2), leading to an almost clearance of
lesional skin [19]. Evaluation of 17 consecutive patients
receiving PUVA bath photochemotherapy (0.2 J/cm2 to
0.5 J/cm2 initial dosage, 1.2 J/cm2 to 3.5 J/cm2 UVA maxi-
mum dose) revealed marked clinical improvement in 13
of 17 persons even after 15 treatment sessions [46]. As
already mentioned above, Kanekura et al. could also verify
the effectiveness of PUVA therapy, beside three patients
with SSc, in one patient exhibiting generalized morphea
[32]. Within the following years, a number of case reports
and serial cases were able to reproduce the positive results
of PUVA therapy in LS, employing higher initial and
cumulative doses and more treatment sessions to achieve
improvement/clearance [47-49]. Recently, Pasic et al.
demonstrated that local PUVA bath may also be of certain
benefit for LS in childhood [34]. Moreover, PUVA cream
therapy has been successfully introduced by Grundmann-
Kollmann et al. in four LS patients (cumulative dose rang-
ing from 67.5 J/cm2 to 121 J/cm2, maximum single dose:
3.5 J/cm2) and, analogous to UVA1 phototherapy,
improvement of linear scleroderma en coup de sabre
treated with topical calcipotriol ointment and PUVA
cream could be observed by Gambichler et al. [50,51].
Extragenital lichen sclerosus et atrophicus
Extragenital LSA is an uncommon skin disease character-
ized by white porcelain-like sclerotic skin lesions predom-BMC Dermatology 2004, 4:11 http://www.biomedcentral.com/1471-5945/4/11
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inantly affecting the flexor surface of the wrists, the upper
part of the trunk, and the axillae. In the common form of
LSA, genital involvement with atrophy of the vulval,
penile, and perianal skin is usually observed [52].
Although LSA has sometimes been considered as a sub-
species of LS, LSA is generally regarded as a separate entity
as to its distinct clinical and histomorphological peculiar-
ities [53-55].
UVA1
The efficiency of UVA1 phototherapy in extragenital LSA
was first established by Kreuter et al. in 2001 [56]. The
authors here report on the improvement of skin status fol-
lowing 40 sessions of long-wave UVA1 irradiation (four
sessions per week for ten weeks, total of 40 treatments, 20
J/cm2 low-dose UVA1 per session, 800 J/cm2 cumulative
dose). In the same year, a subsequent double casuistic was
presented, both receiving the same low-dose UVA1 photo-
therapy and both responding to therapy with an almost
complete clearance of formerly sclerosing lesions [57].
UVA1 phototherapy in localized scleroderma Figure 3
UVA1 phototherapy in localized scleroderma. Macroscopic 
aspects of LS displaying extensive sclerosis on the chest 
before (Fig. 3) and after low-dose UVA1 irradiation resulting 
in a remarkable softening (Fig. 4).
UVA1 phototherapy in localized scleroderma Figure 4
UVA1 phototherapy in localized scleroderma. Macroscopic 
aspects of LS displaying extensive sclerosis on the chest 
before (Fig. 3) and after low-dose UVA1 irradiation resulting 
in a remarkable softening (Fig. 4).
UVA1 phototherapy in extragenital lichen sclerosus et  atrophicus Figure 5
UVA1 phototherapy in extragenital lichen sclerosus et 
atrophicus. Confetti-like lesions of extragenital LSA (Fig. 5) 
and marked improvement of following low-dose UVA1 pho-
totherapy (Fig. 6).
UVA1 phototherapy in extragenital lichen sclerosus et  atrophicus Figure 6
UVA1 phototherapy in extragenital lichen sclerosus et 
atrophicus. Confetti-like lesions of extragenital LSA (Fig. 5) 
and marked improvement of following low-dose UVA1 pho-
totherapy (Fig. 6).BMC Dermatology 2004, 4:11 http://www.biomedcentral.com/1471-5945/4/11
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Only one year later, Kreuter et al. were able to present the
improvement of extragenital LSA in ten patients, all being
treated by the established standard irradiation protocol
[58]. In contrast, low-dose UVA1 phototherapy of mor-
phea with overlying LSA could not completely reverse the
corresponding histopathological changes in a clinical trial
in one patient [40].
PUVA
As far as PUVA therapy in extragenital LSA is concerned,
one case report could demonstrate a promising therapeu-
tic attempt [59]. Interestingly, single UVA1 progressed
from 0.3 to 2.3 J/cm2 resulting in a cumulative dose of
31.7 J/cm2 during a six week period. In addition to the
extragenital manifestation, PUVA cream photochemo-
therapy has also been proven to be even effective in geni-
toanal lesions of LSA [60]. Nevertheless, despite the
absence of any short-term side effect, UVA irradiation of
genital affections should be performed extremely carefully
in order to prevent long-term negative adverse
consequences.
Sclerodermoid graft-versus-host disease
Chronic graft-versus-host disease (GvHD) is an immuno-
logical condition frequently occurring as a late conse-
quence of allogenic bone marrow transplantation. Two
subtypes, cutaneous lichenoid and sclerodermoid, have
been described, based on clinical and histopathological
examinations. Sclerodermoid GvHD is a severe adverse
immunologic reaction with deposition of collagen in the
skin and possibly other soft tissues, resulting in loss of
range of motion and functional capabilities [61].
UVA1
In 2000, Grundmann-Kollmann et al. presented a patient
with chronic sclerodermic GvHD, who did not respond to
conventional chemotherapeutic agents [62]. Low-dose
UVA1 phototherapy was successfully administered four
times a week over six weeks (20 J/cm2 single dose, 480 J/
cm2  cumulative dose) combined with mycophenolate
mofetil therapy. Based on the potentially beneficial effect
of UVA1 phototherapy in scleroderma, Staender et al.
investigated the efficacy of low- or medium-dose UVA1
phototherapy, respectively [63]. Five patients (two of
them after insufficient PUVA treatment) received 50 J/cm2
single-dose UVA1 irradiation five times per week for two
months followed by a subsequent reduction towards
three times weekly. One patient was treated by a stable
dosage of 20 J/cm2 in combination with immunosuppres-
sives and extracorporeal phototherapy. In all cases, ther-
apy led to softening of formerly stiffed sclerotic lesions.
Most recently, the positive effect of UVA1 irradiation was
underlined by Calzavara Pinton et al. [64]. Five patients
exhibiting sclerodermoid GvHD (localized: 4; general-
ized: 1) were treated with medium-dose UVA1 photother-
apy three times weekly (50 J/cm2 single dose, 750 J/cm2 to
1650 J/cm2 UVA1 cumulative dose) resulting in a com-
plete remission in three and a partial improvement in two
patients.
PUVA
Already years ago it has been shown that systemic PUVA
therapy might be of certain benefit to chronic lichenoid
and recalcitrant stages of GvHD, but remains insufficient
in sclerotic forms [65-67]. In 1991, another report of
PUVA therapy for chronic GvHD could only demonstrate
clinical improvement in lichenoid lesions, sclerodermoid
skin involvement did not respond to therapy [68].
Oncoming studies including up to 40 patients were able
to verify the efficiency of therapeutic PUVA administra-
tion, even though only single cases of slightly improved
sclerodermatous lesions could be observed [69,70]. How-
ever, most recently, Leiter et al. performed a successful
PUVA treatment in two patients suffering from scleroder-
moid GvHD [71]. Inasmuch as improvement of skin
involvement is concerned, after a median of 25 treatment
sessions, PUVA treatment resulted in a sharp reduction of
skin thickness reflected by a relative decrease of 72%. Bath
PUVA was administered three to four times per week at
the beginning followed by a subsequent reduction via
twice to finally once weekly until improvement occurred
(34 or 25 sessions, respectively; standard protocol not
described; 64.0 or 14.2 J/cm2 cumulative UVA1, respec-
tively). One of both received additional 667 J/cm2 UVA1
irradiation. Nevertheless, most authors state that UVA
irradiation should only be performed as an adjunct treat-
ment in addition to conventional chemotherapeutic
regimens.
Lupus erythematosus
LE is an autoimmune disease including a wide spectrum
of manifestations in various organ systems. LE specific
skin lesions can be found in over 80% of the patients. Cur-
rently, three epidemiological forms are distinguished: dis-
coid LE, subacute cutaneous LE and systemic LE beside the
presence of a variety of specific subtypes [72].
UVA1
The first study on UVA1 phototherapy in subacute cutane-
ous LE appeared in 1993 [73]. A nine week series of UVA1
phototherapy leading to a cumulative dose of 186 J/cm2
had been administered. Thereafter, an impressive
improvement of LE lesions was noted. In another uncon-
trolled study conducted in 1994, ten patients with sys-
temic LE were treated with 6 J/cm2 for 15 sessions during
a period of three weeks [74]. Four of them continued
treatment for eight months. The authors could verify a
marked clinical improvement combined with a decrease
of autoantibody concentration. Since then, two rand-
omized double-blind placebo-controlled cross-over stud-BMC Dermatology 2004, 4:11 http://www.biomedcentral.com/1471-5945/4/11
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ies were performed. First, McGrath et al. reported in a two-
phase study two groups of patients, one receiving 6 J/cm2
UVA1 five times a week for three weeks followed by a
three week exposure of placebo visible light, the other vice
versa [75]. Twenty-five patients completed this phase of
the study. Both procedures were followed by an
unblinded exposure of progressively decreasing UVA1 lev-
els. Taking clinical as well as serological data in account,
the authors proposed that low-dose UVA1 phototherapy
might be superior to visible light irradiation. Second, Pol-
dermann et al. tried to compare exactly the two different
groups in a total of eleven patients [76]. Although no sta-
tistically significant difference between the two groups
could be evaluated after an exposure of three weeks
including 6 J/cm2 cold-light UVA1 five times weekly, sig-
nificant clinical improvement was restricted to the UVA1
group. Apart from the short term benefit following UVA1
phototherapy, Molina et al. were also able to describe a
long term benefit following low-dose UVA1 treatment
(once/twice per week, 6–15 J/cm2) for a mean impressive
period of 3.4 years in six patients of their former study
[77]. Additionally, recent data of a case report suggest that
UVA1 might contribute to a reversal of brain dysfunction
and may also improve covered discoid lupus lesions via
unknown systemic pathways [78]. As to our knowledge,
no positive effects of PUVA treatment have been reported
so far.
Sclerotic rarities
Eosinophilic fasciitis is a rare disorder disabling joint
motility closely related to profound morphea with a vari-
able response to treatment [79].
UVA1
A case report could verify a significant clinical improve-
ment of eosinophilic fasciitis with low dose UVA1 therapy
four times a week for ten weeks, resulting in a total of 40
treatment sessions, additional to azathioprine treatment.
At each treatment session 20 J/cm2 UVA1 were applied,
resulting in a cumulative dose of 800 J/cm2. Afterwards
the induration had softened markedly and the patient was
able to close the fist again [80].
PUVA
Eosinophilic fasciitis successfully treated with PUVA bath
photochemotherapy was described by Schiener et al. in
2000 [81]. In their study the authors present a case report
of single dose 0.3 J/cm2 PUVA four times a week for period
of 35 treatments including a progression of 0.3 J/cm2
every third session. Subsequently, irradiation frequency
was reduced to three times a week for three weeks or two
times a week for another two weeks resulting in a total of
50 treatment sessions and a cumulative dose of 102.1 J/
cm2.
Pansclerotic morphea of childhood represents a severe
variant of LS, often lethal even in young patients [82].
UVA1
In 1997, Gruss et al. reported the successful administra-
tion of low-dose UVA1 phototherapy in disabling pan-
sclerotic morphea of childhood by the usage of 20 J/cm2
four times a week for eight weeks resulting in a total of 32
treatment sessions, a cumulative dose of 640 J/cm2 UVA1
and a remarkable softening of the skin [83]. Another
recent study could underline the efficacy of UVA exposure
[84].
PUVA
In 1995, Scharffetter-Kochanek et al. presented a success-
ful approach of PUVA therapy in disabling pansclerotic
morphea of a young girl [85]. UVA was administered by a
maximum singe dose of 1.8 J/cm2 four times weekly for
the first two months followed by maintenance on two
treatments per week for another six months. In contrast,
an additional case report demonstrated one patient failing
to respond to PUVA therapy as an adjunct to penicilla-
mine treatment [86].
Scleromyxedema is a variant of lichen myxedematosus
exhibiting erythematous, sclerotic and stiffed lesions
beside lichenoid papules caused by an extensive dermal
deposition of glycosaminoglycans with only little ten-
dency of spontaneous remission [87-89].
PUVA
Following a first promising attempt of PUVA treatment as
early as 1984 [90], Adachi et al. tried systemic PUVA pho-
tochemotherapy in lichen myxedematosus administering
35 treatment session at a cumulative dose of 202 J/cm2
[91]. In this respect, the authors speculate on the inhibi-
tion of dermal fibroblasts and synthesis of mucopolysac-
charides as a possible mechanism of action. Nevertheless,
Schirren et al. achieved only limited beneficial effect after
combined chlorambucil and PUVA therapy [92].
Scleredema adultorum Buschke, occurring secondarily to
diabetes or independently, is an uncommon party sclero-
dermoid disease characterized by erythematous indurated
skin and a mucinous dermal infiltration exhibiting
increased collagen deposition [93,94].
PUVA
Both PUVA bath and PUVA cream have been reported to
be of benefit in patients suffering from Buschke's disease.
First, bath PUVA therapy was tested in 1998 by Hager et al.
in case of three patients exhibiting resistant scleredema
adultorum [95]. A median of 59 treatments and a cumu-
lative dose of 245.7 J/cm2 UVA was applied resulting in a
substantial clinical improvement in all three patients.BMC Dermatology 2004, 4:11 http://www.biomedcentral.com/1471-5945/4/11
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Later, Grundmann-Kollmann and co-workers introduced
cream PUVA in a patient responding excellently to UVA
irradiation (35 sessions, 114.5 J/cm2  total cumulative
dose) [96]. As to our knowledge, UVA/UVA1 photother-
apy have so far not been taken into account neither in
scleredema adultorum nor in scleromyxedema.
POEMS syndrome, characterized by polyneuropathy,
organomegaly, endocrinopathy and elevated levels of a
Table 1: Overview of the different phototherapeutic strategies within the main groups of sclerotic connective tissue diseases. 
[Categories: A – double-blind, randomized, placebo-controlled; B – open, randomised; C – open, non-randomized; D – case series; E – 
case report]
Disease Therapy Dosage Experience Comments
Systemic sclerosis UVA - - requires evaluation
UVA128–31 low-/medium-dose E, C benefit, especially suited for acrosclerosis and partial 
body exposure
PUVA18,32–34 medium-dose E, D bath application in childhood discussed
Localized scleroderma UVA36,37 low-dose C benefit, no further evaluation
UVA138–45 low-/medium-/high-dose D, C no exact recommendation in favor to best dosage, 
benefit, combination with calcipotriol where 
appropriate, successful in childhood/adolescence
PUVA19,32,34,46–51 high-dose E, D questionable efficacy, extreme variance in dosage, 
combination (cream) with calcipotriol in childhood
Extragenital lichen sclerosus 
et atrophicus
UVA - - requires evaluation
UVA140,56–58 low-dose E, D, C effectiveness, disputable in combined morphea/lichen 
sclerosis et atrophicus
PUVA59,60 low-dose E benefit, careful cream therapy for genitoanal lesions 
where appropriate
Sclerodermoid graft- vs-host 
disease
UVA - - requires evaluation
UVA162–64 low-/medium-dose E, D partial efficacy, medium-dose possibly more effective 
than low-dose, combined UV/immunosuppressive 
therapy
PUVA65–71 medium-dose E, D, C skeptical effectiveness, potentially adjunct therapy in 
addition to conventional chemotherapy, more effective 
in lichenoid than sclerodermoid lesions
Lupus erythematosus UVA - - requires evaluation
UVA173–78 low-dose D, C, A benefit in occasional cases, long-term application
PUVA - - requires evaluation
Table 2: Synopsis of recent case reports decribing various phototherapeutic alternatives in a number of sclerotic rarities. [Categories: 
A – double-blind, randomized, placebo-controlled; B – open, randomised; C – open, non-randomized; D – case series; E – case report]
Disease Therapy Dosage Experience Comments
Eosinophilic fasciitis UVA180 low-dose E benefit, no valid data available
PUVA81 medium-dose E
Pansclerotic morphea UVA84 low-dose E possible efficacy as an adjunct therapy,
UVA183 low-dose E no valid data available
PUVA85,86 medium-dose E
Scleromyxedema PUVA90–92 high-dose E controversial, possible efficacy as an adjunct therapy, 
no valid data available
Scleredema adultorum Buschke PUVA95,96 high-dose E, D possible therapeutic alternative, cream therapy, no 
valid data available
POEMS UVA198 low-dose E benefit, no valid data available
Bleomycin-induced scleroderma UVA199 low-dose E limited success, no valid data available
Pansclerotic porphyria cutanea tarda UVA1101 medium-dose E benefit, no valid data availableBMC Dermatology 2004, 4:11 http://www.biomedcentral.com/1471-5945/4/11
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monoclonal protein, often exhibit scleroderma-like skin
changes [97].
UVA1
Severe therapy-resistant cutaneous sclerodermatous
lesions of one patient suffering from POEMS syndrome
showed a remarkable improvement following low-dose
UVA1 phototherapy given for 35 treatment sessions [98].
Bleomycin-induced SSc-like scleroderma may occur fol-
lowing application of the antitumor agent bleomycin
[99].
UVA1
The authors report a case of drug induced scleroderma
after bleomycin administration given due to a malignant
testicular seminoma. Low-dose UVA1 phototherapy (20 J/
cm2 UVA1, three to four times a week) caused an initial
improvement of skin condition, but could not stop the
overall progress [99].
Pansclerotic porphyria cutanea tarda is an uncommon
subtype of cutaneous porphyria [100]. Simultaneously,
massive exposure of organic solvents may also result in
sclerotic modifications.
UVA1
In 2003, Karamfilov et al. could stop progression of skin
affection by the use of medium-dose UVA1 phototherapy
combined with intensive physiotherapy and oral gluco-
corticoids in a patient with pansclerotic porphyria cutanea
tarda after chronic exposure to organic solvents [101].
UVA1 irradiation was applied for a total of 30 sessions, a
single-dose of 40 J/cm2 and a corresponding cumulative
dose of 1200 J/cm2.
Discussion
Beside a high number of different side indications, sys-
temic and especially topical PUVA treatment have been
shown to provoke a remarkable clearance of psoriatic
plaques and infiltrated lesions of cutaneous T cell lym-
phoma. On the other hand, UVA1 phototherapy achieved
practical value in the treatment of inflammatory and
malignant T cell related skin diseases. Typical indications
regularly include exacerbated atopic dermatitis, cutaneous
T cell lymphoma, parapsoriasis or mucinosis follicularis
due to the induction of T cell apoptosis and dermal
immunoregulation. By reason of notable collateral induc-
tion of dermal collagenase activity, UVA irradiation was
subsequently introduced as a treatment alternative in LS
and other sclerotic collagenoses in both dermatology and
rheumatology.
As far as the extensive accumulation of collagen is con-
cerned several investigations demonstrated the long-wave
UVA-induced stimulation of the synthesis of specific
mRNA-levels of various matrix-metalloproteinases in cul-
tured human fibroblasts, probably due to their lower anti-
oxidant capacity and involvement of the protein kinase C
pathway [21,102-110]. Simultaneously, an elevation of
interstitial collagenase m-RNA and protein expression can
be determined immunohistochemically and by the use of
nucleic-acid in-situ hybridization in dermal fibroblasts
[21,111]. Furthermore, several studies provided evidence
that at least UVA1 irradiation induces the formation of
several cytokines and soluble factors e.g. interleukin-1
and/or interleukin-6 stimulating the synthesis of colla-
genase, while some immunomodulatory cytokines
remain unaltered [112,113].
On the other hand, UVA1 irradiation has been shown to
initiate apoptotic cell death in dermal T lymphocytes
[114,115]. A shift of the balance between protooncogenes
(e.g., bcl-2) and tumor suppressor genes (e.g., p53)
towards the induction of apoptosis seems to be one of the
major effects of UVA1 irradiation [10]. Beside the involve-
ment of singlet oxygen as an early intermediate in colla-
genase induction, oxidative stress has also been proven to
induce lipid peroxidation in cytoplasmatic membranes
and to be responsible for DNA damage [116,117]. There-
fore, one causal factor of membrane alterations might be
the (P)UVA-induced generation of reactive oxygen spe-
cies, such as singlet oxygens or superoxide anions and
hydroxyl radicals leading to lipid peroxidation, structural
and functional modifications of membranes character-
ized by altered fluidity, increased permeability and inacti-
vation of cellular enzymes and transport proteins [116-
119]. Furthermore, singlet oxygen is able to open mito-
chondrial megachannels, releasing apoptosis initiating
factor (AIF) and cytochrom c heading towards indirect
DNA damage in T cells [116,120,121]. Besides, UVA1-
induced apoptosis is triggered by receptor mechanisms,
e.g. by the alternative activation of the FAS/FAS-ligand
(APO-1, CD95) system in peripheral T cells
[114,116,122].
If and to what extent additional modulations of impaired
endothelial cells might also contribute to the postthera-
peutic clinical and histological improvement still has to
be investigated [123]. Nevertheless, the efficacy of differ-
ent regimens of UVA phototherapy might probably, at
least in parts, be due to the mechanisms of action as men-
tioned above.
Inasmuch as LE and other autoimmune disorders are con-
cerned, a transparent mechanism of action remains
obscure. Immunohistologically, LE is at least character-
ized by an inflammatory T cell derived infiltration mainly
of the T helper subtype combined with an impairment of
T and B lymphocyte regulation, dysregulated dendritic cellBMC Dermatology 2004, 4:11 http://www.biomedcentral.com/1471-5945/4/11
Page 10 of 14
(page number not for citation purposes)
abnormalities and defective clearance of immune com-
plexes and autoantigens [124-126]. Analogous to the scle-
rosing disorders as mentioned above, induction of
apoptosis in T lymphocytes may also represent the com-
mitted step of UVA exposure in LE. Simultaneously, UVA
has been shown to directly affect presence, function and
morphology of dermal and epidermal Langerhans cells,
which may result in a suppression of cell-mediated immu-
nity and a disruption of autoreactive T lymphocyte, B cell
and Langerhans cell stimulating processes [127-131].
Controversially, UV radiation is often associated with
exacerbating skin eruptions and photosensitivity is
actually a diagnostic criterion of LE. Nevertheless, in how
far improvement of skin condition after repeated irradia-
tion might be due to adaptive decreased oxidative stress
upon subsequent UVA exposures has to be evaluated
[131].
Despite an extensive therapeutic administration of UVA
irradiation, relatively little data are available concerning
possible acute and long-term side effects. Usually, patients
exhibit a dose-dependent tanning of the skin, which has
been described to appear following a single minimal pig-
menting dose of 50 J/cm2  UVA1 [132,133], whereas
UVA1-induced erythema can usually only be observed
after ≥ 90 J/cm2 single dose UVA1 [134]. After UVA1 expo-
sure, individuals of all skin types appear to develop more
or less immediate pigment darkening that is due to a
reversible photochemical reaction (oxidation of melanin
and its precursors and metabolites). In contrast, even after
a comparably lower dosage, broad-band UVA irradiation
is able to provoke erythema and delayed tanning which is
due to an enzymatically controlled production of melanin
polymers. After topical or systemic PUVA treatment
patients exhibit the characteristic methoxsalen dose-
dependent PUVA erythema ranging from three to six days
following irradiation [135,136]. Additionally, systemic
PUVA is often associated with nausea or vomitus. How-
ever, by considering exclusion criteria such as an autoim-
mune disease associated abnormally increased
photosensibility, solar and heat induced urticaria or a his-
tory of polymorphous light eruption and, especially in the
case of PUVA therapy, by the consequent posttherapeutic
use of potent sun protection, additional clinically relevant
acute side effects may usually not be expected.
As far as long-term side effects are concerned no definite
prediction has yet been taken. Controlled studies dealing
with the carcinogenesis induced by broad-band UVA
sources are still rare. Nevertheless, the induction of der-
mal hyperplastic elastic fibers resulting in early skin age-
ing following a cumulative dose of 4000–8000 J/cm2
UVA1 seems to be imminent [6]. Additionally, as already
reported above, the induction of collagenases released by
dermal fibroblasts is known to be an important cofactor
within this process [9,137]. On the other hand, carcino-
genesis of UVA1 irradiation is still poorly understood.
Taking the elimination of the potentially procarcinoge-
netic wavelength ranging from 315–320 nm into account,
one might speculate on the possibly lower risk of UVA
irradiation [138]. Indeed, possible melanogenetic long-
term effects of long-wavelength UV irradiation (induction
of malignant melanomas) have previously been discussed
[139,140]. Simultaneously, animal studies suggested the
induction of squamous cell carcinomas even though pro-
voked by 220 kJ/m2 for a period of 265 days [6]. Until
today, no assignment to humans could be achieved. How-
ever, at least concentrated PUVA photochemotherapy has
been found to be related to potential mutagenesis and the
increased occurrence of squamous cell carcinomas as well
as malignant melanomas in psoriatic patients [9,141-
143].
Moreover, recent investigations concerning the effects of
UVA1 irradiation on human dermal endothelium
revealed the initiation of apoptotic cascades even after a
comparably low dose of single 80 J/cm2 UVA1 radiation.
Due to the penetration of up to 20% of UVA to the level
of dermal vasculature, the induction of the programmed
cell death cascades may develop to one of the main side
effects of UVA phototherapeutic strategies [144].
Even though especially in case of LE sunlight exposure has
been postulated to induce exacerbation in as much as half
of the patients, courses of UVA irradiation can also be
used in such disease. In this respect, UVA2 and UVB seem
to be responsible for the induction of LE eruptions [145].
Nevertheless, different studies provide strong evidence
that apoptosis associated with a shift of the balance
between p53 and bcl-2, simultaneously one of the main
mechanisms of action concerning UVA phototherapy,
may play a role in the pathogenesis and activity of LE and
might to correlate with the sequential progress of LE skin
lesions [146,147].
As the peak of dermatological therapeutic usage of UVA
irradiation still seems to rise, scientific research engage-
ment is needed in order to rate its potential long-lasting
negative impact. Therefore, until the evaluation of firm
data UVA phototherapy should most likely be restricted in
the number of cycles per year, treatment should be super-
vised by an experienced dermatologist and a UV pass
book should be issued.
Conclusion
Today, by considering this widespread range of clinical
and experimental studies, one might clearly conclude that
different regimens of UVA phototherapy have simultane-
ously been developed to effective, often well-tolerated
and beneficial therapeutic strategies in the treatment of aBMC Dermatology 2004, 4:11 http://www.biomedcentral.com/1471-5945/4/11
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variety of sclerotic skin diseases such as SSc, LS, chronic
GvHD, extragenital LSA or sclerodermoid rarities and
other disorders affecting the connective tissue. In this
respect, the controlled application of UVA irradiation
seems to exhibit a comparably tolerable risk/benefit ratio
as a minimum in case of these precise indications. Fur-
thermore, UVA phototherapy might also be considered as
an optional treatment in both the cutaneous and systemic
forms of LE, although the mechanism of action remains
difficult to understand.
Nevertheless, therapeutic application of UVA photother-
apy, especially of long-wave UVA1 phototherapy, is still
'under construction' as to its limited availability apart
from selective centers of excellence and mostly uncon-
trolled pilot investigations or case reports especially as far
as PUVA or conventional UVA1 phototherapy in sclero-
dermic skin affections or autoimmune disorders are con-
cerned. From our point of view there is no doubt that UVA
phototherapy could by far be much more frequently used
in the treatment of connective tissue lesions of the skin
and, due to its ability to affect dermal vascular structure,
even of extracutaneous manifestations. However, addi-
tional research efforts are required to determine an exem-
plary clear-cut catalogue of indications responding to
UVA irradiation. Therefore, oncoming controlled rand-
omized studies evaluating the efficacy of UVA photother-
apy in connective tissue diseases should not only focus on
the assessment of further innovative indications, but also
on the comparison between phototherapeutic agents and
conventional immunosupressive/-modulating regimens
as for example systemic glucocorticoids, azathioprine,
methotrexate or cyclophosphamide as well as on the con-
firmation of former uncontrolled reports, not only
because of the fact that the natural history of fibrotic dis-
orders includes a period of inflammation/rapid indura-
tion followed by a prolonged period of regression even in
untreated patients, but also in order to expand its usage to
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